NTIC

NTIC is a 50-year-old corrosion-prevention franchise (ZERUST brand, 65+ countries) plus a smaller bioplastics arm (Natur-Tec), with a notably clean balance sheet: $72.1M of equity against $103M of assets, $7.25M cash (up 46.4%), and a 1.85x current ratio. At $8.83 the $83.7M market cap is just 1.16x book and ~1.0x sales — a valuation that already prices in distress, which is the core reason this is a hold rather than a sell. The franchise and the balance sheet are intact; the earnings are not.

The problem is that FY2025 earnings power evaporated. Revenue was essentially flat (-1.0% to $84.2M), but operating income fell 67.3% to $2.57M and net income collapsed 99.7% to $17.6K — a 3.1% operating margin and a 0.0% net margin/ROE. Gross profit fell 6.2% (margin 37.6%) faster than revenue, and operating cash flow dropped 58.5% to $2.44M. The MD&A attributes part of this to a deliberate choice: 'During fiscal 2025, NTIC made significant strategic investments in its ZERUST oil and gas sales infrastructure.' That reframes the collapse as partly self-inflicted growth spend on a flat revenue base rather than pure demand loss — a genuine mitigant — but with operating income down two-thirds and net income at zero, the payoff is entirely unproven and the model's heavy reliance on a global subsidiary/JV network (China, India, ASEAN, Brazil, Europe) adds FX and equity-income volatility below the operating line.